Provided by Tiger Fintech (Singapore) Pte. Ltd.

Park Hotels & Resorts Inc.

10.00
+0.01000.10%
Post-market: 10.040.0400+0.40%17:59 EDT
Volume:3.48M
Turnover:34.70M
Market Cap:2.02B
PE:9.90
High:10.03
Open:9.98
Low:9.82
Close:9.99
Loading ...

5 Top Stocks Paying Big Dividends

Zacks
·
08 Feb

TransCode Therapeutics Announces Completion of Cohort 3 Initial Dosing with Lead Candidate in Phase 1 Clinical Trial

PR Newswire
·
06 Feb

Agios to Webcast Conference Call of Fourth Quarter and Full Year 2024 Financial Results on February 13, 2025

GlobeNewswire
·
06 Feb

Do Options Traders Know Something About Park Hotels (PK) Stock We Don't?

Zacks
·
05 Feb

Pasithea Therapeutics Announces Positive Safety Review Committee (SRC) Recommendation from its ongoing Phase 1 Clinical Trial of PAS-004 in Advanced Cancer

GlobeNewswire
·
05 Feb

CHMP Gives Nod to Expanded Use of J&J's Rybrevant & AZN's Imfinzi

Zacks
·
05 Feb

Should Value Investors Buy Park Hotels & Resorts (PK) Stock?

Zacks
·
04 Feb

Park Hotels & Resorts (PK) Loses -6.09% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

Zacks
·
04 Feb

Rezolute Provides Update on its Phase 3 sunRIZE Study of Ersodetug for the Treatment of Hypoglycemia Due to Congenital Hyperinsulinism

GlobeNewswire
·
04 Feb

Why Park Hotels & Resorts (PK) Is Sinking Today

Insider Monkey
·
04 Feb

Park Hotels & Resorts Is Maintained at Neutral by UBS

Dow Jones
·
04 Feb

UBS Adjusts Price Target on Park Hotels & Resorts to $13 From $15, Keeps Neutral Rating

MT Newswires Live
·
04 Feb

Invivyd Announces Positive Phase 1/2 Clinical Data for VYD2311, a Monoclonal Antibody Designed to be a Superior Alternative to COVID-19 Vaccination for the Broad Population

GlobeNewswire
·
03 Feb

PLX: Revisiting the Thesis

Zacks Small Cap Research
·
03 Feb

CervoMed Provides Update on Neflamapimod DLB Program as Part of Presentation at the 8th International Lewy Body Dementia Conference

GlobeNewswire
·
31 Jan

Adial Pharmaceuticals Announces Positive Clinical Study Results from the AD04-103 Pharmacokinetics Study of AD04 for the Treatment of Alcohol Use Disorder

GlobeNewswire
·
29 Jan

EXCLUSIVE: Adial Pharmaceuticals Reveals Positive Pharmacokinetics Study Results Of AD04 For Alcohol Use Disorder

Benzinga
·
29 Jan

Sonnet BioTherapeutics Further Expands Global Intellectual Property Portfolio with Issuance of EU Patent for FHAB® Platform Technology

GlobeNewswire
·
28 Jan

BofA Securities Adjusts Park Hotels & Resorts Price Target to $16 From $16.50

MT Newswires Live
·
27 Jan

Park Hotels & Resorts (PK) Receives a Buy from Compass Point

TIPRANKS
·
27 Jan